Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C27H33N3OS |
Molar mass | 447.64 g·mol−1 |
3D model ( JSmol) | |
|
NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma. [1] It has reasonable selectivity for the CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related CB1 receptor. [2]
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C27H33N3OS |
Molar mass | 447.64 g·mol−1 |
3D model ( JSmol) | |
|
NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma. [1] It has reasonable selectivity for the CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related CB1 receptor. [2]
Phytocannabinoids ( comparison) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Synthetic cannabinoid receptor agonists / neocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Allosteric CBRTooltip Cannabinoid receptor ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||
Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
|
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |